HUP0102334A2 - Paroxetin-metánszulfonát, eljárás az előállítására, valamint a vegyületet tartalmazó gyógyszerkészítmények - Google Patents

Paroxetin-metánszulfonát, eljárás az előállítására, valamint a vegyületet tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0102334A2
HUP0102334A2 HU0102334A HUP0102334A HUP0102334A2 HU P0102334 A2 HUP0102334 A2 HU P0102334A2 HU 0102334 A HU0102334 A HU 0102334A HU P0102334 A HUP0102334 A HU P0102334A HU P0102334 A2 HUP0102334 A2 HU P0102334A2
Authority
HU
Hungary
Prior art keywords
compound
preparation
pharmaceutical compositions
compositions containing
paroxetine methanesulfonate
Prior art date
Application number
HU0102334A
Other languages
English (en)
Inventor
Andrew Simon Craig
Victor Witold Jacewicz
Alan David Jones
Deirdre O'keeffe
Michael William John Urquhart
Neal Ward
Original Assignee
Smithkline Beecham Plc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269380&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0102334(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9814316.7A external-priority patent/GB9814316D0/en
Priority claimed from GBGB9821732.6A external-priority patent/GB9821732D0/en
Priority claimed from GBGB9902935.7A external-priority patent/GB9902935D0/en
Application filed by Smithkline Beecham Plc. filed Critical Smithkline Beecham Plc.
Publication of HUP0102334A2 publication Critical patent/HUP0102334A2/hu
Publication of HUP0102334A3 publication Critical patent/HUP0102334A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A találmány olyan kristályos formájú paroxetin-metánszulfonátravonatkozik, amely kristályos forma - egyebek mellett - a következőkarakterisztikus IR csúcsokkal rendelkezik: 1603, 1513, 1194, 1045,946, 830, 776, 601, 554 és 539 < 4 cm-1; és/vagy a következőkarakterisztikus XRD csúcsokkal rendelkezik: 8, 3, 10, 5, 15, 6, 16,3, 17, 7, 18, 2, 19, 8, 20, 4, 21, 5, 22, 0, 22, 4, 23, 8, 24, 4, 25,0, 25, 3, 25, 8, 26, 6, 30, 0, 30, 2 és 31, 6 < 0, 2 fok 2 theta. Atalálmány kiterjed a vegyület előállítási eljárására, gyógyászatialkalmazására, valamint a vegyületet tartalmazógyógyszerkészítményekre is. Ó
HU0102334A 1998-07-02 1999-04-23 Paroxetine methanesulfonate, process for its preparation and pharmaceutical compositions containing the compound HUP0102334A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9814316.7A GB9814316D0 (en) 1998-07-02 1998-07-02 Novel compounds
GBGB9821732.6A GB9821732D0 (en) 1998-10-06 1998-10-06 Novel compound
GBGB9902935.7A GB9902935D0 (en) 1999-02-10 1999-02-10 Novel compound

Publications (2)

Publication Number Publication Date
HUP0102334A2 true HUP0102334A2 (hu) 2002-05-29
HUP0102334A3 HUP0102334A3 (en) 2003-12-29

Family

ID=27269380

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102334A HUP0102334A3 (en) 1998-07-02 1999-04-23 Paroxetine methanesulfonate, process for its preparation and pharmaceutical compositions containing the compound

Country Status (35)

Country Link
US (4) US6063927A (hu)
EP (5) EP1020464B1 (hu)
JP (1) JP2002519422A (hu)
KR (1) KR20010053336A (hu)
CN (1) CN1127502C (hu)
AR (2) AR011759A1 (hu)
AT (4) ATE251155T1 (hu)
AU (4) AU713131B3 (hu)
BE (3) BE1011664A6 (hu)
BR (1) BR9911682A (hu)
CA (1) CA2269999A1 (hu)
CH (1) CH689805A8 (hu)
DE (5) DE29907248U1 (hu)
DK (7) DK199900554A (hu)
ES (4) ES2209428T3 (hu)
FI (2) FI4209U1 (hu)
FR (2) FR2780728B1 (hu)
GB (5) GB2377637A (hu)
GR (3) GR990100140A (hu)
HK (1) HK1037877A1 (hu)
HU (1) HUP0102334A3 (hu)
IE (5) IES81166B2 (hu)
IL (1) IL140628A (hu)
IT (1) IT1312540B1 (hu)
LU (1) LU90388B1 (hu)
NL (4) NL1011875C2 (hu)
NO (1) NO319030B1 (hu)
NZ (1) NZ509180A (hu)
PL (1) PL345214A1 (hu)
PT (4) PT102291B (hu)
SE (1) SE9901462A0 (hu)
SI (3) SI0970955T1 (hu)
SK (1) SK20262000A3 (hu)
TR (1) TR200100054T2 (hu)
WO (1) WO2000001694A1 (hu)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
DE69818981D1 (de) * 1997-02-27 2003-11-20 Ajinomoto Kk Vorrichtung und verfahren zur kristallisation
PT994872E (pt) * 1997-06-10 2001-09-28 Synthon Bv Composto de 4-fenilpiperidina
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
US20040028582A1 (en) * 1999-03-10 2004-02-12 Smithkline Beecham Corporation Crystallization process for producing fine crystal products
USPP12225P2 (en) 1999-06-01 2001-11-27 Florfis Ag Geranium plant named ‘Fislamda’
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
WO2000078290A2 (en) * 1999-06-22 2000-12-28 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a salt of paroxetine
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US6306435B1 (en) 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
WO2002017921A2 (en) * 2000-08-28 2002-03-07 Synthon B.V. Paroxetine compositions and processes for making the same
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
NL1017421C2 (nl) * 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
US20040225128A1 (en) * 2001-08-02 2004-11-11 Callewaert George Leo Paroxetine isethionate salt, process of preparation and use in the treatment of depression
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
WO2006018318A1 (en) * 2004-08-18 2006-02-23 Synthon B.V. Liquid paroxetine compositions
WO2006023347A1 (en) * 2004-08-20 2006-03-02 Alpharma, Inc. Paroxetine formulations
KR100672184B1 (ko) 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
AU2006235230B8 (en) * 2005-04-07 2010-08-26 Chata Biosystems, Inc. Flow path conditioner system
US20070112031A1 (en) * 2005-11-14 2007-05-17 Gant Thomas G Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
US8722884B2 (en) * 2005-12-01 2014-05-13 Verastem, Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
KR20090118110A (ko) * 2007-03-09 2009-11-17 노파르티스 아게 3-(1ｈ-인돌-3-일)-4-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-피롤-2,5-디온의 염
US20100249166A1 (en) 2007-09-19 2010-09-30 Xy, Inc. Differential evaporation potentiated disinfectant system
US8119688B2 (en) * 2007-09-19 2012-02-21 Xy, Llc Differential evaporation potentiated disinfectant system
FR2926552B1 (fr) * 2008-01-23 2010-03-26 Biocodex Procede de preparation de particules de stiripentol ayant une granulometrie definie
CN103961333B (zh) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 甲磺酸帕罗西汀胶囊及其制备方法
CN104523645A (zh) * 2014-11-20 2015-04-22 美吉斯制药（厦门）有限公司 甲磺酸帕罗西汀片芯及其包衣片的制备方法
US11111373B2 (en) 2018-12-05 2021-09-07 Chi Mei Corporation Polymethacrylate composition and optical device made therefrom, and display apparatus

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE99678C (hu) *
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0190496A3 (en) * 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
EP0223334B1 (en) * 1985-08-10 1991-07-10 Beecham Group Plc Process for the preparation of aryl-piperidine carbinols
DE3677712D1 (de) * 1985-10-21 1991-04-04 Honda Motor Co Ltd Methode zur steuerung des spulenstroms eines magnetventils, das die saufluftmenge eines innenverbrennungsmotors steuert.
ES2058061T3 (es) * 1985-10-25 1994-11-01 Beecham Group Plc Derivado de piperidina, su preparacion y su uso como medicamento.
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
JPS63141967A (ja) * 1986-11-21 1988-06-14 エイ・エッチ・ロビンス・カンパニー・インコーポレーテッド 抗アレルギー薬として有用な１−アリールオキシー４−［（４−アリール）−１−ピペラジニル］−２−ブタノール
GB8714707D0 (en) * 1987-06-23 1987-07-29 Beecham Group Plc Chemical process
DK715988D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Etherifikation og dealkylering af piperidin-derivater samt intermediater
DK716088D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Reduktion af piperidin-dion-derivater samt intermediat
JPH06502854A (ja) * 1990-11-24 1994-03-31 ビーチャム・グループ・パブリック・リミテッド・カンパニー 老年痴呆、過食症、片頭痛または食欲不振の治療用のパロキセチンの使用
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
JP2773587B2 (ja) * 1992-11-30 1998-07-09 東レ株式会社 Ｏ，ｏ´−ジアシル酒石酸無水物の製造法
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
US5546683A (en) * 1993-09-29 1996-08-20 Clark; George J. Bucket attachment device with remote controlled retractable pins
IT1274241B (it) * 1993-12-03 1997-07-15 Smithkline Beecham Farma Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5668134A (en) * 1994-01-28 1997-09-16 G. D. Searle & Co. Method for preventing or reducing photosensitivity and/or phototoxicity reactions to medications
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
GB2297550B (en) * 1995-02-06 1997-04-09 Smithkline Beecham Plc Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
AR001982A1 (es) * 1995-02-06 1998-01-07 Smithkline Beecham Plc Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
CA2216934A1 (en) * 1995-04-03 1996-10-10 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
WO1996036636A1 (en) * 1995-05-17 1996-11-21 Novo Nordisk A/S Process for preparing 4-aryl-piperidine derivatives
JP2813768B2 (ja) * 1995-05-24 1998-10-22 農林水産省家畜衛生試験場長 ***診断用ペプチドおよび当該ペプチドを含有する***診断用抗原
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
AU701386B2 (en) * 1995-10-31 1999-01-28 Merck & Co., Inc. Process for preparing substituted azetidinones
IT1276160B1 (it) * 1995-11-22 1997-10-27 Recordati Chem Pharm Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
GB9526645D0 (en) * 1995-12-28 1996-02-28 Chiroscience Ltd Stereoselective synthesis
ES2117557B1 (es) * 1996-02-29 1999-07-01 Ferrer Int Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina.
JP3446468B2 (ja) * 1996-04-15 2003-09-16 旭硝子株式会社 ピペリジンカルビノール類の製造方法
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride
JP3882224B2 (ja) * 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
ES2331937T3 (es) * 1996-06-13 2010-01-20 Sumitomo Chemical Company, Limited Derivados de piperidina como intermediarios para la preparacion de paroxetina y procedimiento de preparacion de los mismos.
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
US5672609A (en) * 1996-07-18 1997-09-30 Eli Lilly And Company Pyridine compounds, intermediates compositions and methods of use
CA2187128A1 (en) * 1996-10-04 1997-06-26 K. S. Keshava Murthy New and useful polymorph of anhydrous paroxetine hydrochloride
PT994872E (pt) * 1997-06-10 2001-09-28 Synthon Bv Composto de 4-fenilpiperidina
WO1999040084A1 (en) * 1998-02-06 1999-08-12 Smithkline Beecham Plc Salts of paroxetine
AP2000001907A0 (en) * 1998-03-16 2000-09-30 Smithkline Beecham Plc Crystalline form of paroxetine.
EA200001050A1 (ru) * 1998-04-09 2001-04-23 Смитклайн Бичам Плс Малеат пароксетина
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat

Also Published As

Publication number Publication date
SI1089996T1 (en) 2004-04-30
US20020035130A1 (en) 2002-03-21
GB9909505D0 (en) 1999-06-23
EP1020464A1 (en) 2000-07-19
SE9901462A0 (sv) 2000-01-03
GB0119695D0 (en) 2001-10-03
GB0216752D0 (en) 2002-08-28
ES2149044T3 (es) 2000-10-16
CN1127502C (zh) 2003-11-12
CN1315949A (zh) 2001-10-03
NO991944D0 (no) 1999-04-23
SE9901462L (hu)
LU90388B1 (fr) 2001-01-29
NL1011875C2 (nl) 2000-03-24
AR018197A1 (es) 2001-10-31
BE1012403A5 (fr) 2000-10-03
US20020193406A1 (en) 2002-12-19
GB0026487D0 (en) 2000-12-13
TR200100054T2 (tr) 2001-06-21
PT102291B (pt) 2002-07-31
AR011759A1 (es) 2000-09-13
ATE251155T1 (de) 2003-10-15
DK199900234U1 (da) 2000-12-22
AU2392899A (en) 2000-01-20
EP1288214A1 (en) 2003-03-05
FR2802098A1 (fr) 2001-06-15
NL1011875A1 (nl) 2000-01-07
GR1003350B (el) 2000-03-29
HUP0102334A3 (en) 2003-12-29
PL345214A1 (en) 2001-12-03
GB2339428A (en) 2000-01-26
NL1012272C1 (nl) 1999-07-12
DE69900007T2 (de) 2001-06-07
ES2158778B1 (es) 2002-03-16
PT102291A (pt) 2000-05-31
ES2209428T3 (es) 2004-06-16
CA2269999A1 (en) 2000-01-02
KR20010053336A (ko) 2001-06-25
EP0970955A1 (en) 2000-01-12
ES2158778A1 (es) 2001-09-01
DE69911774T2 (de) 2004-08-05
BR9911682A (pt) 2001-12-26
NZ509180A (en) 2001-06-29
FR2780728A1 (fr) 2000-01-07
GB2377637A (en) 2003-01-22
PT970955E (pt) 2000-11-30
FI112077B (fi) 2003-10-31
NO319030B1 (no) 2005-06-06
NL1012271C2 (nl) 1999-09-23
WO2000001694A1 (en) 2000-01-13
IES20000893A2 (en) 2001-05-30
DE69911774D1 (de) 2003-11-06
SK20262000A3 (sk) 2001-07-10
CH689805A8 (fr) 2000-02-29
DE19918588A1 (de) 2000-01-27
AU3619199A (en) 2000-01-24
EP1020464B1 (en) 2001-07-04
JP2002519422A (ja) 2002-07-02
AU732211C (en) 2004-05-06
ES2157881T3 (es) 2001-09-01
AU713131B3 (en) 1999-11-25
DK199900554A (da) 2000-01-03
IES81166B2 (en) 2000-05-31
GB2336364A (en) 1999-10-20
GB2352395A (en) 2001-01-31
US6063927A (en) 2000-05-16
SI1020464T1 (en) 2001-12-31
IE990344A1 (en) 2000-05-03
BE1012420A6 (fr) 2000-10-03
DK1020464T3 (da) 2001-09-24
IT1312540B1 (it) 2002-04-22
US20010023253A1 (en) 2001-09-20
NL1011874C1 (nl) 1999-07-12
EP1089996B1 (en) 2003-10-01
IL140628A (en) 2004-06-20
DK1089996T3 (da) 2004-02-09
NO991944L (no) 2000-01-03
IES990343A2 (en) 2000-01-02
PT1020464E (pt) 2001-10-30
SE9901462D0 (sv) 1999-04-23
ATE195121T1 (de) 2000-08-15
AU713877B3 (en) 1999-12-09
GR3034328T3 (en) 2000-12-29
DE60000003D1 (de) 2001-08-09
GB2367003A (en) 2002-03-27
DE69900007D1 (de) 2000-09-07
FIU990190U0 (fi) 1999-04-23
AU732211B2 (en) 2001-04-12
BE1011664A6 (fr) 1999-11-09
IE20000633A1 (en) 2001-10-17
FR2780728B1 (fr) 2001-02-16
DK200000390U1 (da) 2000-12-27
AT3185U3 (de) 2000-01-25
FI990922A (fi) 2000-01-03
GB9920332D0 (en) 1999-11-03
GR3036208T3 (en) 2001-10-31
SI0970955T1 (en) 2001-02-28
NL1012271A1 (nl) 1999-07-12
PT1089996E (pt) 2004-02-27
CH689805A5 (fr) 1999-11-30
GB2336364B (en) 2000-05-10
EP0970955B1 (en) 2000-08-02
IES20000894A2 (en) 2001-05-30
AT3185U2 (de) 1999-11-25
DK199900176U3 (da) 1999-08-13
DK0970955T3 (da) 2000-10-09
DK199900234U4 (da) 2000-12-22
GB2352395B (en) 2004-02-11
FI990922A0 (fi) 1999-04-23
GR990100140A (el) 2000-03-31
DE29907248U1 (de) 1999-09-09
FI4209U1 (fi) 1999-11-10
HK1037877A1 (en) 2002-02-22
DE60000003T2 (de) 2002-03-21
IL140628A0 (en) 2002-02-10
EP1089996A1 (en) 2001-04-11
ITMI990866A1 (it) 2000-10-23
ATE202777T1 (de) 2001-07-15
EP1020463A1 (en) 2000-07-19

Similar Documents

Publication Publication Date Title
HUP0102334A2 (hu) Paroxetin-metánszulfonát, eljárás az előállítására, valamint a vegyületet tartalmazó gyógyszerkészítmények
HUP0203257A2 (hu) Atorvastatin kalcium polimorf módosulatai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
CA2431068A1 (en) Crystalline forms of atorvastatin
EP1004578A3 (en) 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
HUP0002987A2 (hu) Cefdinir diciklohexil-amin sója és eljárás a só előállítására valamint a vegyület sójából történő felszabadítására
MX9605741A (es) Clorhidrato cristalino del (r)-(-)-2-{n-[4-(1,1-dioxido-3-oxo-2,3-dihidro-benzisotiazol-2-il)-butil ]-aminometil} cromano.
HUP0202400A2 (hu) Prosztaglandinszármazékot tartalmazó készítmény külső elválasztási rendellenességek kezelésére
EP1429757B8 (en) Crystalline forms of fluvastatin sodium
WO2001083439A3 (fr) NOUVELLE FORME CRISTALLINE η DU SEL DE TERT-BUTYLAMINE DU PERINDOPRIL, SON PROCEDE DE PREPARATION, ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT
CA2163837A1 (en) Crystalline Paclitaxel Hydrates
CA2450093A1 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
IL112622A (en) Iminoalkylamino or aminoalkylideneamino camptothecin derivatives, process for their preparation and pharmaceutical compositions containing them
MY136269A (en) Novel diphenylazetidinone, process for its preparation, medicaments comprising this compound and their use
MEP9309A (en) Novel oligosaccharides, preparation method and pharmaceutical compositions containing the same
CA2419314A1 (en) Preparation of risperidone
BG106389A (en) Crystals of the sodium salt of pravastatin
HUP0200580A2 (hu) Celecoxib polimorf kristályos formái, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
CA2412047A1 (en) Shortened synthesis of 3,3-diarylpropylamine derivatives
CA2340224A1 (en) Nimesulide containing topical pharmaceutical compositions
HUP0000960A2 (hu) Porlasztva szárított paroxetin-hidroklorid, ennek előállítása, alkalmazása és a vegyületet tartalmazó gyógyszerkészítmények
AU3184300A (en) Process for the preparation of a bioavailable oral dosage form of cefuroxime axetil
CA2137748A1 (en) Amidinophenylalanine derivatives, a process for their preparation, their use and compositions containing these as anticoagulants
HUP0105308A2 (hu) Eletriptán-hidrobromid-monohidrát, eljárás az előállítására és a vegyületet tartalmazó gyógyszerkészítmények
AU2002245005A1 (en) Thiazolopyrimidine derivatives and use thereof as antagonists of the cx3 cr1 receptor
NZ332545A (hu)

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees